Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
Recruiting · NCT06965114 · Registry updated 2026-07-31Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, hairy cell leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoproliferative syndrome, neoplasm, refractory hairy cell leukemia | Recruiting | Phase 1 / Phase 2 | 2026-07-31 | NCT06965114 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| NCI - Center for Cancer Research | Bethesda | United States | 13 |
| Ohio State University Comprehensive Cancer Center | Columbus | United States | 548 |
| University of Virginia Cancer Center | Charlottesville | United States | 206 |
| UPMC Hillman Cancer Center | Pittsburgh | United States | 330 |